Pilot and Pharmacokinetic Studies of Solubilized Estradiol Administered

Vaginally in a Softgel Capsule

James H. Pickar, M.D., F.A.C.O.G.

Disclosures

• Consulted for:• Wyeth / Pfizer• Ausio Pharmaceuticals• Besins Healthcare• Shionogi• Metagenics• TherapeuticsMD

Introduction

• TX-004HR is a new softgel vaginal capsule under development• Two bioavailability studies (10µg and 25µg) were

conducted comparing TX-004HR vaginal estradiol softgel capsules (VagiCap™) versus approved estradiol vaginal tablets (Vagifem®)• A single center, randomized, placebo-controlled,

clinical pilot study was conducted to test the safety and efficacy of the 10mcg dose of TX-004HR (VagiCap) versus placebo when give daily for 14 days

TX-004HR VagiCap™

Study Design-Pharmacokinetic Studies

• Two single dose, randomized, open label, two-way crossover, bioavailability studies were conducted. Each had a 14 day wash-out between doses. There were 36 healthy postmenopausal women in each study.

• Subjects were included if they were generally healthy, 40-65 years old with BMI between 18.5-29.9. They were required to have a normal ECG, chest X-ray, lab values, breast and gynecologic exam. E2< 50 pg/ml, FSH >40 IU/l, no vaginal bleeding for 12 months or 6 months post bi-lateral oophorectomy (w or w/o hysterectomy).

Study Design-Pharmacokinetic Studies

• Subjects stayed in the research facility, fasted the night before, were fed a standard diet and estrogen blood levels were measured at 13 time points ( -1.0, -0.5, 0.0, 1.0, 2.0, 4.0, 6.0, 8.0, 10.0, 12.0, 14.0, 18.0, 24.0 hours postdose) via in-dwelling catheter.

• Thirty-five women completed the 10mcg study and 36 completed the 25mcg study.

PK Study Results - Estradiol Baseline Adjusted

10mcg Study 25 mcg Study

PK Parameter Geometric Mean ±SD

Test (T) Reference (R)

Cmax (pg/ml) 14.38 20.38

AUC 0-24 (pg.hr/ml) 49.62 132.92

T max (hr) 1.75 9.28

PK Parameter Geometric Mean ±SD

Test (T) Reference (R)

Cmax (pg/ml) 23.08 42.70

AUC 0-24 (pg.hr/ml) 89.21 292.06

T max (hr) 1.85 11.18

Comparison detected as statistically significant (p < 0.05)

0 6 12 18 240

10

20

30

40

time after dosing (hrs)mea

n p

lasm

a c

on

cen

tra

tio

n (

pg

/mL

)

ReferenceTest

0 6 12 18 240

10

20

30

40

time after dosing (hrs)mea

n p

lasm

a c

on

cen

tra

tio

n (

pg

/mL

)

ReferenceTest

PK Study Results – Estrone Baseline Adjusted

10mcg Study 25 mcg Study

PK Parameter Geometric Mean ±SD

Test (T) Reference (R)

Cmax (pg/ml) 5.15 6.98

AUC 0-24 (pg.hr/ml) 24.24 48.24

T max (hr) 5.87 9.07

PK Parameter Geometric Mean ±SD

Test (T) Reference (R)

Cmax (pg/ml) 10.69 23.58

AUC 0-24 (pg.hr/ml) 50.22 165.47

T max (hr) 5.14 11.48

Comparison detected as statistically significant (p < 0.05)

0 6 12 18 240

5

10

15

time after dosing (hrs) mea

n p

las

ma

con

cen

trat

ion

(p

g/m

L)

ReferenceTest

0 6 12 18 240

5

10

15

time after dosing (hrs)mea

n p

lasm

a c

on

cen

tra

tio

n (

pg

/mL

)

ReferenceTest

Study Design-Phase 2 Clinical Study

• A randomized, double blind, placebo controlled pilot trial evaluated the safety and efficacy of 10mcg of TX-004HR in reducing moderate to severe symptoms of vulvovaginal atrophy in healthy postmenopausal women following once daily administration for 14 days.

• n=50; aged 40-75yrs; • BMI≤34 kg/m²; • with ≤ 5% superficial cells and a vaginal pH>5.0;• at least one moderate to severe symptom of

vulvovaginal atrophy

Clinical Study Results • In this clinical trial, significantly higher mean percent

increases from baseline were observed with Test vs placebo for superficial cells (35% vs 4%, p=0.0002) and intermediate cells (13% vs 4%, p=0.0002) at 2 weeks.

• The mean percent decrease from baseline in parabasal cells was significantly greater with Test vs placebo (54% vs 5%, p=0.0001), as was the mean decrease in vaginal pH (0.97 vs 0.34, p=0.0002).

• The Test group also had significantly greater improvements in vaginal epithelial integrity and secretions than the placebo arm. Vaginal symptom improvement was similar between groups, likely due to the small size and short duration of the study.

Clinical Study Results • Out of the 50 subjects enrolled into the study, one subject

discontinued due to an eye contusion (AE, not related) and one for family emergency.• Fourteen subjects (11-TX-004HR, 3-placebo) had

experienced a total of 17 AEs(13-TX004HR, 4-placebo) over the course of the trial. Most were reported as not related or possibly related.• No serious AEs were reported.

Conclusions

• Studies showed that both the 10µg and the 25µg doses of TX-004HR, a novel estradiol vaginal softgel capsule, were safe and well tolerated. • Systemic exposure with both doses was significantly less

than with the equivalent doses of an approved vaginal estradiol tablet.• The clinical study of the 10µg dose of TX-004HR given daily

for 2 weeks demonstrated significant improvement in vaginal cytology and pH compared with placebo.• Based on the results of these studies an additional lower

dose of 4µg is being studied in the phase 3 trial.

Coauthors

Julia M. Amadio, M.B.A.John M. Hill, M.D.Brian A. Bernick, M.D.Sebastian Mirkin, M.D.

Thank You